Biotechnology company argenx has agreed to acquire Unnatural Products, a discovery company that works with macrocyclic peptides. The proposed deal would add peptide research capabilities to argenx’s existing immunology platform.
The transaction includes an upfront payment of $550 million and up to $595 million in additional payments tied to development and regulatory milestones. That brings the potential total consideration to approximately $1.15 billion if the specified milestones are reached.
The deal is subject to customary closing conditions, with argenx expecting it to close by the end of the year.
What the companies bring together
Unnatural Products works on macrocyclic peptides, which are ring-shaped molecules. The company’s discovery approach could complement argenx’s antibody engineering and immunology research, according to the proposed acquisition terms.
The companies have collaborated for more than two years, and argenx was already a minority shareholder. Under the agreement, argenx would acquire the remaining shares.
The potential scientific goal is to explore medicines that could be taken orally or have longer-lasting effects. Those are development possibilities, not treatments that are ready for patients. Any candidate medicines would need to go through research, testing and regulatory review.
Payment depends partly on future progress
The deal separates the upfront payment from the additional milestone-based consideration. The $550 million upfront portion is to be paid from argenx’s cash on hand.
The remaining amount, up to $595 million, would depend on specified development and regulatory milestones. This means the full $1.15 billion value is not guaranteed; it depends on whether the conditions are met.
Milestone structures are common in biotech deals because the value of a research platform depends on whether it produces viable drug candidates and whether those candidates advance through development.
Research team and development plans
Following closing, Unnatural Products’ current team and leadership are expected to remain in Santa Cruz, California, and lead discovery work within an agreed framework. argenx would contribute clinical development and commercialization capabilities.
Combining research teams can give a company access to new methods and expertise. It can also take time to align different scientific processes and decide which projects to advance.
The transaction reflects continuing interest in platforms that can identify and develop new medicines. In this case, the focus is on combining peptide discovery with antibody engineering for immunology research.
What to watch
The first milestone is completion of the acquisition, which remains conditional. After that, attention will turn to how the combined teams use the platform and whether research produces candidates that progress through development.
Drug discovery carries substantial uncertainty. A promising molecular approach may fail during preclinical work or clinical trials, and successful development can take years.
For now, the agreement gives argenx access to additional discovery capabilities while assigning part of the potential purchase price to future progress. The deal’s scientific impact will depend on what the research produces after closing.